Chart Events
Performance Outlook
| Previous Close | 97.00 |
| Open | 97.17 |
| Bid | 96.93 x 900 |
| Ask | 96.95 x 800 |
| Day's Range | 96.49 - 97.20 |
| 52 Week Range | 79.98 - 105.61 |
| Volume | |
| Avg. Volume | 1,481,244 |
| Market Cap | 199.482B |
| Beta (5Y Monthly) | 0.51 |
| PE Ratio (TTM) | 25.14 |
| EPS (TTM) | 3.86 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.50 (3.61%) |
| Ex-Dividend Date | Mar 09, 2023 |
| 1y Target Est | 112.75 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NVS
Related Research
- Novartis AGAnalyst Report: Novartis AGNovartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.RatingFair ValueEconomic Moat22 hours agoMorningstar
BenzingaEyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
Tuesday, the FDA said it received reports of patients developing T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies. The FDA has determined that the risk of T-cell malignancies applies to all currently approved BCMA-directed and CD19-directed genetically modified autologous CAR T-cell immunotherapies. Since 2017, six CAR T-cell therapies have been approved by the FDA:
ZacksCAR T-Cell Therapies Under FDA Watch on Reports of Malignancies
The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.
ZacksNovartis (NVS) Raises Mid-Term Sales Outlook; Outlines Strategy
Novartis (NVS) increases its sales guidance for the mid-term (2022-2027) and outlines its growth strategy as a pure-play pharmaceutical company.
